Synonyms: PQ-912 | PQ912
Compound class:
Synthetic organic
Comment: Varoglutamstat (PQ912) is a glutaminyl cyclase inhibitor [2]. It inhibits post-translational pyroglutamyl modification at the N-terminal of substrate proteins. This modification has been identified as contributing to the neurotoxicity of amyloid-β peptides deposited in Alzheimer's disease, making glutaminyl cyclase inhibitors of therapeutic interest for disease-modifying potential [1,6].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Varoglutamstat (PQ912) is a clinical candidate for the treatment of Alzheimer's disease. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02389413 | Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease | Phase 2 Interventional | Vivoryon Therapeutics N.V. | 3 | |
NCT04498650 | A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD | Phase 2 Interventional | Vivoryon Therapeutics N.V. | 4 | |
NCT03919162 | A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD | Phase 2 Interventional | Vivoryon Therapeutics N.V. | ||
NCT02190708 | Effects of PQ912 on the Pharmacokinetics of Midazolam and Omeprazole | Phase 1 Interventional | Vivoryon Therapeutics N.V. |